Vaishampayan Vaishampayan U U Thakur Thakur A A Rathore Rathore R R Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients Prostate Cancer Prostate Cancer 2015 2015 2015 2015 285193 285193 supplied-pmid 25802762? Here, ERBB2 is linked to prostate carcinoma.